Trioplus Pharmaceuticals Private Limited

Trioplus Pharmaceuticals Private Limited is an Indian pharmaceutical exporter established on July 23, 2013, in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U74999MH2013PTC246040. It operates as a private limited company, classified as a non-government entity, and is unlisted on stock exchanges. The authorized and paid-up capital of the company is ₹100,000 each.

The registered office is located at Unit No.106, Samruddhi Commercial Complex, Chincholi Bunder Road, Mindspace, Malad (West), Mumbai, Maharashtra, 400064. The company is engaged in pharmaceutical retail and distribution activities within the professional, scientific, and technical sector.

As of the latest available data, Trioplus Pharmaceuticals has reported a significant decrease in revenue, with a 47.71% decline in the financial year ending March 31, 2023. Profitability also experienced a substantial fall, with a 103.98% decrease in profit during the same period. The company's net worth dipped by 1.09% in the same fiscal year.

Specific details regarding Trioplus Pharmaceuticals' manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's operations primarily focus on the export of finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This strategic focus suggests that the company may rely on third-party manufacturers or contract manufacturing organizations (CMOs) for production. However, without explicit information, the exact nature of their manufacturing arrangements remains speculative.

Trioplus Pharmaceuticals is led by two directors:

• Kunal Surendra Mehra: Appointed on July 23, 2013, he serves as a director of the company.

• Neelav Rajmohan Agarwal: Also appointed on July 23, 2013, he holds the position of director.

The company's financial statements for the fiscal year ending March 31, 2023, were filed on March 31, 2023, and the Annual General Meeting (AGM) was held on September 30, 2023.

Trioplus Pharmaceuticals' export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's total export value is $1.1 million USD, with 32 shipments across two therapeutic categories: antifungals and antihistamines & allergy medications. The top five products exported are Ketoconazole ($600K, Rank #8, 1.5% market share) and Chlorpheniramine ($494K, Rank #12, 1.1% market share). The primary markets for these products are not specified in the available data.

Trioplus Pharmaceuticals' export data does not specify its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's focus on finished pharmaceutical formulations suggests potential opportunities in these regions, especially if the products meet the World Health Organization's (WHO) prequalification standards. However, without explicit information, the extent of the company's penetration into these markets remains unclear.

The available data does not provide detailed insights into Trioplus Pharmaceuticals' geographic diversification or concentration risks. The company's export portfolio is concentrated entirely on its top five products, indicating a lack of diversification in its product offerings. This concentration could pose risks if market dynamics change or if there are regulatory challenges in the primary export markets. A more diversified product portfolio and geographic presence could mitigate such risks.

Specific information regarding Trioplus Pharmaceuticals' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, is not publicly available. The company's export data does not specify its presence in the U.S. market, and without explicit information, the extent of its engagement with the FDA remains unclear.

There is no publicly available information indicating that Trioplus Pharmaceuticals has obtained World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certifications. These certifications are crucial for accessing certain international markets, and the absence of such certifications may limit the company's ability to export to regions that require them.

Trioplus Pharmaceuticals is registered with the Central Drugs Standard Control Organisation (CDSCO) in India, as indicated by its Corporate Identification Number (CIN) U74999MH2013PTC246040. The company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. Without this information, it is challenging to assess the company's compliance with Indian regulatory requirements.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Trioplus Pharmaceuticals. The company's export data does not specify any regulatory actions in its target markets. However, the absence of such information does not necessarily indicate a clean regulatory record.

Trioplus Pharmaceuticals operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. The company's top five products—Ketoconazole and Chlorpheniramine—are common in the antifungal and antihistamine categories, respectively. Major competitors in these categories include global pharmaceutical companies with established market presence and extensive product portfolios. Trioplus Pharmaceuticals' market share of 1.5% for Ketoconazole and 1.1% for Chlorpheniramine indicates a modest position in the market. The company's lack of diversification in both product offerings and geographic markets may limit its ability to compete effectively against larger, more diversified competitors.

Trioplus Pharmaceuticals' focus on finished pharmaceutical formulations, particularly in the antifungal and antihistamine categories, allows it to cater to specific therapeutic needs. However, the company's product portfolio is highly concentrated, with the top five products accounting for 100% of its exports. This lack of diversification may limit its ability to adapt to changing market demands and could pose risks if there are shifts in therapeutic trends or regulatory environments.

Trioplus Pharmaceuticals' current strategic direction appears to be focused on exporting finished pharmaceutical formulations in the antifungal and antihistamine categories. The company's lack of diversification in both product offerings and geographic markets suggests a need for strategic expansion to mitigate risks associated with market concentration. Future growth may depend on obtaining necessary certifications, such as WHO prequalification and EU GMP, to access a broader range of international markets.

Specific information regarding Trioplus Pharmaceuticals' manufacturing facilities, including locations, capacities, and specializations, is not publicly disclosed. The company's reliance on third-party manufacturers or contract manufacturing organizations (CMOs) is inferred from its focus on finished pharmaceutical formulations. Without explicit information, it is challenging to assess the company's track record, export volume consistency, and reliability indicators.

Importers should verify the following certifications when considering Trioplus Pharmaceuticals as a supplier:

• FDA Registration: To ensure compliance with U.S. regulations, importers should confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official database.

• WHO-GMP Certification: To access markets requiring WHO prequalification, importers should verify that the company's manufacturing facilities hold WHO-Good Manufacturing Practice (GMP) certification. This can be confirmed through the WHO's official website.

• EU GMP Certification: For access to European markets, importers should ensure that the company's manufacturing facilities are certified under EU GMP standards. This can be verified through the European Medicines Agency (EMA).

• ISO Certification: Importers should check for ISO certifications related to quality management systems (e.g., ISO 9001) to assess the company's commitment to quality standards. Verification can be done through the International Organization for Standardization (ISO) website.

When conducting due diligence on Trioplus Pharmaceuticals, importers should consider the following steps:

• Verify Regulatory Compliance: Confirm that the company's manufacturing facilities are registered with relevant regulatory bodies, such as the FDA, WHO, and EMA.

• Assess Financial Health: Review the company's financial statements to evaluate